Treatment
VRC07-523LS clinical trials
We’re tracking 5 recruiting studies that include VRC07-523LS, each written for real people, not researchers, below.
Recruiting studies
- NCT07390955RecruitingPhase 1
Safety study of three anti-HIV antibodies in healthy adults
This study is testing three experimental antibodies (ePGT121v1-LS, PGDM1400LS, and VRC07-523LS) that may help prevent HIV. It’s looking at their safety and how long they stay in the body. Healthy volunteers without HIV can join.
Birmingham, AlabamaAges 18–55 - NCT06517693RecruitingPhase 1
HIV antibody safety study for newborns at risk
This study tests whether giving a combination of two lab-made antibodies (PGT121.414.LS and VRC07-523LS) to newborns exposed to HIV during pregnancy is safe and how the body processes them. It may help protect infants from getting HIV after birth.
Los Angeles, CaliforniaAges Up to 3 days - NCT06484335RecruitingPhase 1
HIV vaccine study with treatment pause for Thai adults
This study tests whether adding an experimental vaccine can help your immune system control HIV during a temporary break from your antiretroviral therapy (ART). If you have been on ART since shortly after infection with a suppressed viral load, this trial could help you understand if a 'functional cure' is possible.
Pathum Wan, BangkokAges 18–60 - NCT05719441RecruitingPhase 2
Testing HIV antibodies plus early HIV treatment for possible remission
This trial tests whether giving two powerful HIV-fighting antibodies (called broadly neutralizing monoclonal antibodies) along with starting standard HIV medications soon after infection can help control the virus without needing daily pills. If successful, it might allow people to take a 'treatment pause' while keeping their immune system healthy.
Birmingham, AlabamaAges 18–70 - NCT02140255RecruitingPhase 1/Phase 2
Intensive early HIV treatment in newborns to aim for remission
This study gives very early, intensive HIV medicine to infants diagnosed with HIV and follows them closely to see if HIV can go into remission (stop being detectable without ongoing treatment). It may help families understand whether treating right after birth can change a child’s long-term HIV outlook.
La Jolla, CaliforniaAges Up to 2 days
What VRC07-523LS is being studied for
Conditions with recruiting VRC07-523LS studies.
Common questions
- Are there clinical trials studying VRC07-523LS?
- Yes. Clin2 currently lists 5 recruiting studies that include VRC07-523LS, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a VRC07-523LS trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is VRC07-523LS an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether VRC07-523LS or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.